Ru-Fang Yeh
Overview
Explore the profile of Ru-Fang Yeh including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
39
Citations
3964
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Bloehdorn J, Braun A, Taylor-Weiner A, Jebaraj B, Robrecht S, Krzykalla J, et al.
Nat Commun
. 2021 Sep;
12(1):5395.
PMID: 34518531
Knowledge of the genomic landscape of chronic lymphocytic leukemia (CLL) grows increasingly detailed, providing challenges in contextualizing the accumulated information. To define the underlying networks, we here perform a multi-platform...
2.
Sandhu S, McNeil C, LoRusso P, Patel M, Kabbarah O, Li C, et al.
Invest New Drugs
. 2019 Aug;
38(3):844-854.
PMID: 31385109
Background Endothelin B receptor (ETR) is involved in melanoma pathogenesis and is overexpressed in metastatic melanoma. The antibody-drug conjugate DEDN6526A targets ETR and is comprised of the humanized anti-ETR monoclonal...
3.
Dolly S, Wagner A, Bendell J, Kindler H, Krug L, Seiwert T, et al.
Clin Cancer Res
. 2016 Jan;
22(12):2874-84.
PMID: 26787751
Purpose: This first-in-human phase I trial assessed the safety, tolerability, and preliminary antitumor activity of apitolisib (GDC-0980), a dual inhibitor of class I PI3K, and mTOR kinases. Experimental Design: Once-daily...
4.
Weisser M, Yeh R, Duchateau-Nguyen G, Palermo G, Nguyen T, Shi X, et al.
Blood
. 2014 Jun;
124(3):420-5.
PMID: 24916506
Addition of rituximab (R) to fludarabine and cyclophosphamide (FC) has significantly improved patient outcomes in chronic lymphocytic leukemia (CLL). Whether baseline gene expression can identify patients who will benefit from...
5.
Brauer M, Zhuang G, Schmidt M, Yao J, Wu X, Kaminker J, et al.
Clin Cancer Res
. 2013 May;
19(13):3681-92.
PMID: 23685835
Purpose: The aim of this study was to identify conserved pharmacodynamic and potential predictive biomarkers of response to anti-VEGF therapy using gene expression profiling in preclinical tumor models and in...
6.
Fridlyand J, Yeh R, Mackey H, Bengtsson T, Delmar P, Spaniolo G, et al.
Contemp Clin Trials
. 2013 May;
36(2):624-35.
PMID: 23648396
In the past decade, the cost of drug development has increased significantly. The estimates vary widely but frequently quoted numbers are staggering-it takes 10-15 years and billions of dollars to...
7.
Dufour A, Palermo G, Zellmeier E, Mellert G, Duchateau-Nguyen G, Schneider S, et al.
Blood
. 2013 Mar;
121(18):3650-7.
PMID: 23525797
In chronic lymphocytic leukemia (CLL) patients, disruptions of the TP53 tumor suppressor pathway by 17p13 deletion (del17p), somatic TP53 mutations, or downregulation of microRNA-34a have been associated with a poor...
8.
Qin H, Blaschke K, Wei G, Ohi Y, Blouin L, Qi Z, et al.
Hum Mol Genet
. 2012 Jan;
21(9):2054-67.
PMID: 22286172
Pluripotent stem cells are derived from culture of early embryos or the germline and can be induced by reprogramming of somatic cells. Barriers to reprogramming that stabilize the differentiated state...
9.
Stinson S, Lackner M, Adai A, Yu N, Kim H, OBrien C, et al.
Sci Signal
. 2011 Aug;
4(186):pt5.
PMID: 21868360
Compared with the luminal subtype, the basal-like subtype of breast cancer has an aggressive clinical behavior, but the reasons for this difference between the two subtypes are poorly understood. We...
10.
Stinson S, Lackner M, Adai A, Yu N, Kim H, OBrien C, et al.
Sci Signal
. 2011 Jun;
4(177):ra41.
PMID: 21673316
The basal-like subtype of breast cancer has an aggressive clinical behavior compared to that of the luminal subtype. We identified the microRNAs (miRNAs) miR-221 and miR-222 (miR-221/222) as basal-like subtype-specific...